Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists engineer self-destructing bacteria to kill cancer cells
Salmonella bacteria
Hasty and his team synchronised the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumour.
In vivo method minimises damage to surrounding cells

Scientists at the University of California and the Massachusetts Institute have discovered a therapeutic approach to cancer that minimises damage to surrounding cells.

A study published in the journal Nature describes how researchers engineered self-destructing bacteria that release anti-cancer drugs within tumours.

“In synthetic biology, one goal of therapeutics is to target disease sites and minimise damage,” said lead author Jeff Hasty, professor of bioengineering and biology at UC San Diego.

In the study, Hasty and his team synchronised the bacteria to release bursts of known cancer drugs when a bacterial colony self-destructs within the tumour.

Researchers say the use of bacteria to deliver cancer drugs in vivo is 'enticing' because conventional chemotherapy doesn't always reach the inner regions of a tumour.

Importantly, the researchers observed the combination of chemotherapy and the gene products produced by the bacterial circuit consistently reduced tumour size.

“The new work by Jeff Hasty and team is a brilliant demonstration of how theory in synthetic biology can lead to clinically meaningful advances,” said Jim Collins, a founder of the field of synthetic biology.

“Over a decade ago during the early days of the field, Jeff developed a theoretical framework for synchronising cellular processes across a community of cells. Now his team has shown experimentally how one can harness such effects to create a novel, clinically viable therapeutic approach.”

Become a member or log in to add this story to your CPD history

Building Great Workplaces webinars return

News Story 1
 BVA has announced a new series of its Building Great Workplaces lunchtime webinars.

Launching from 16 July, the sessions will explore patient safety, motivation, client communication and more.

Its first webinar, exploring neurodiversity in the workplace, will take place at 1pm on Thursday, 16 July. It will feature guest speakers from The Vet Project, a group which supports neurodiversity in veterinary environments.

The following three webinars take place in September, October and November.

Booking is open on the BVA website 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.